This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (292)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Prostate Disease  • Oncology  • Prostate Cancer  • Alert me on articles by topic

Peter C. Albertsen, MD; James A. Hanley, PhD; Donald F. Gleason, MD, PhD; Michael J. Barry, MD

JAMA. 1998;280:975-980.

Context.— The appropriate therapy for men with localized prostate cancer is uncertain. Until results of clinical trials are available, men and their physicians need guidance.

Objective.— To estimate survival based on a competing risk analysis stratified by age at diagnosis and histologic findings for men diagnosed as having clinically localized prostate cancer and who were managed conservatively.

Design.— Retrospective cohort study.

Setting.— Connecticut Tumor Registry.

Patients.— A total of 767 men with localized prostate cancer diagnosed between 1971 and 1984, aged 55 to 74 years at diagnosis, either not treated or treated with immediate or delayed hormonal therapy, and followed up for 10 to 20 years after diagnosis.

Main Outcome Measures.— Estimates of the probability of dying from prostate cancer or other competing hazards.

Results.— Men with tumors that have Gleason scores of 2 to 4, 5, 6, 7, and 8 to 10 face a 4% to 7%, 6% to 11%, 18% to 30%, 42% to 70%, and 60% to 87% chance, respectively, of dying from prostate cancer within 15 years of diagnosis depending on their age at diagnosis.

Conclusions.— Men whose prostate biopsy specimens show Gleason score 2 to 4 disease face a minimal risk of death from prostate cancer within 15 years of diagnosis. Conversely, men whose biopsy specimens show Gleason score 7 to 10 disease face a high risk of death from prostate cancer when treated conservatively, even when cancer is diagnosed as late as age 74 years. Men with Gleason score 5 or 6 tumors face a modest risk of death from prostate cancer that increases slowly over at least 15 years of follow-up.

From the Division of Urology, University of Connecticut Health Center, Farmington (Dr Albertsen); Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec (Dr Hanley); and the General Medicine Unit, Massachusetts General Hospital, Boston (Dr Barry). Dr Gleason is retired from private practice in Minneapolis, Minn.

RELATED ARTICLES

Comparing Treatments for Localized Prostate Cancer—Persisting Uncertainty
Gerald W. Chodak
JAMA. 1998;280(11):1008-1010.
EXTRACT | FULL TEXT  

Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
Anthony V. D'Amico, Richard Whittington, S. Bruce Malkowicz, Delray Schultz, Kenneth Blank, Gregory A. Broderick, John E. Tomaszewski, Andrew A. Renshaw, Irving Kaplan, Clair J. Beard, and Alan Wein
JAMA. 1998;280(11):969-974.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Profile-specific survival estimates: Making reports of clinical trials more patient-relevant
Julien and Hanley
Clin Trials 2008;5:107-115.
ABSTRACT  

Histological Diagnosis of Prostate Cancer in Korean Men Aged 70 79 Years
Shim et al.
Jpn J Clin Oncol 2007;0:hym093v1-6.
ABSTRACT | FULL TEXT  

Comparison of Stage at Diagnosis of Cancer in Patients Who Are on Dialysis versus the General Population
Taneja et al.
CJASN 2007;2:1008-1013.
ABSTRACT | FULL TEXT  

Assessing Individual Risk for Prostate Cancer
Nam et al.
JCO 2007;25:3582-3588.
ABSTRACT | FULL TEXT  

Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men
Wong et al.
JAMA 2006;296:2683-2693.
ABSTRACT | FULL TEXT  

Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.
Reeves et al.
Clin. Cancer Res. 2006;12:6018-6022.
ABSTRACT | FULL TEXT  

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Kelloff et al.
Clin. Cancer Res. 2006;12:3661-3697.
ABSTRACT | FULL TEXT  

Predictors of Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy
Zhou et al.
JCO 2005;23:6992-6998.
ABSTRACT | FULL TEXT  

Stage Migration and Grade Inflation in Prostate Cancer: Will Rogers Meets Garrison Keillor
Thompson et al.
JNCI J Natl Cancer Inst 2005;97:1236-1237.
FULL TEXT  

Statins and Prostate Cancer Risk: A Case-Control Study
Shannon et al.
Am J Epidemiol 2005;162:318-325.
ABSTRACT | FULL TEXT  

In patients with early prostate cancer, is surgery better than watchful waiting?
Alibhai and Gogov
CMAJ 2005;172:1682-1682.
FULL TEXT  

20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen et al.
JAMA 2005;293:2095-2101.
ABSTRACT | FULL TEXT  

The Likelihood That PSA Detection of Early Prostate Cancers Is Associated With High Mortality
Louria
Arch Intern Med 2005;165:702-702.
FULL TEXT  

Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes
Lotan et al.
JCO 2005;23:1911-1920.
ABSTRACT | FULL TEXT  

Management of localised prostate cancer
DTB 2004;42:81-85.
ABSTRACT | FULL TEXT  

Natural History of Early Localized Prostate Cancer
Osborn and Chodak
JAMA 2004;292:1549-1549.
FULL TEXT  

Localized Prostate Cancer: Quality of Life Meets Whitmore's Legacy
Bermejo et al.
JNCI J Natl Cancer Inst 2004;96:1348-1349.
FULL TEXT  

Identification of Clinically Significant Prostate Cancer by Prostate-Specific Antigen Screening
Smith et al.
Arch Intern Med 2004;164:1227-1230.
ABSTRACT | FULL TEXT  

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level <=4.0 ng per Milliliter
Thompson et al.
NEJM 2004;350:2239-2246.
ABSTRACT | FULL TEXT  

Prostate-Specific Antigen Screening in Elderly Men
Lu-Yao et al.
JNCI J Natl Cancer Inst 2003;95:1792-1797.
ABSTRACT | FULL TEXT  

Prostate cancer management: (1) an update on localised disease
Bott et al.
Postgrad. Med. J. 2003;79:575-580.
ABSTRACT | FULL TEXT  

Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?
Alibhai et al.
JCO 2003;21:3318-3327.
ABSTRACT | FULL TEXT  

The Influence of Finasteride on the Development of Prostate Cancer
Thompson et al.
NEJM 2003;349:215-224.
ABSTRACT | FULL TEXT  

The Prevention of Prostate Cancer -- The Dilemma Continues
Scardino
NEJM 2003;349:297-299.
FULL TEXT  

Integrative Tumor Board: Recently Diagnosed Prostate Cancer
Saxe
Integr Cancer Ther 2003;2:65-73.
 

Radical prostatectomy as treatment for prostate cancer
Jewett et al.
CMAJ 2003;168:44-45.
FULL TEXT  

Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era
Kakehi
Jpn J Clin Oncol 2003;33:1-5.
ABSTRACT | FULL TEXT  

Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris and Lohr
ANN INTERN MED 2002;137:917-929.
ABSTRACT | FULL TEXT  

Determinants of Prostate Cancer-Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate Cancer
D'Amico et al.
JCO 2002;20:4567-4573.
ABSTRACT | FULL TEXT  

Language and Medicine: Thinking and Talking About Alzheimer's Disease
Goodwin
Gerontologist 2002;42:293-296.
FULL TEXT  

Occurrence of NKX3.1 C154T Polymorphism in Men with and without Prostate Cancer and Studies of Its Effect on Protein Function
Gelmann et al.
Cancer Res. 2002;62:2654-2659.
ABSTRACT | FULL TEXT  

RESPONSE: Re: Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval
Hoedemaeker et al.
JNCI J Natl Cancer Inst 2002;94:228-229.
FULL TEXT  

Factors Associated With Initial Therapy for Clinically Localized Prostate Cancer: Prostate Cancer Outcomes Study
Harlan et al.
JNCI J Natl Cancer Inst 2001;93:1864-1871.
ABSTRACT | FULL TEXT  

Prostate Cancer: Contrast-enhanced US for Detection
Halpern et al.
Radiology 2001;219:219-225.
ABSTRACT | FULL TEXT  

Prostate Cancer: What Is the Future Role for Imaging?
Thornbury et al.
Am. J. Roentgenol. 2001;176:17-22.
FULL TEXT  

Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials
Valicenti et al.
JCO 2000;18:2740-2746.
ABSTRACT | FULL TEXT  

Comparison of Recommendations by Urologists and Radiation Oncologists for Treatment of Clinically Localized Prostate Cancer
Fowler et al.
JAMA 2000;283:3217-3222.
ABSTRACT | FULL TEXT  

Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step?
Oh and Kantoff
JCO 1999;17:3664-3675.
ABSTRACT | FULL TEXT  

Prostate-Specific Antigen Testing of Older Men
Carter et al.
JNCI J Natl Cancer Inst 1999;91:1733-1737.
ABSTRACT | FULL TEXT  

Urology
Litwin
JAMA 1999;281:495-496.
FULL TEXT  

Avoiding the Unintended Consequences of Growth in Medical Care: How Might More Be Worse?
Fisher and Welch
JAMA 1999;281:446-453.
ABSTRACT | FULL TEXT  

No Simple Answer for Localized Prostate Cancer
JWatch General 1998;1998:1-1.
FULL TEXT  

Comparing Treatments for Localized Prostate Cancer--Persisting Uncertainty
Chodak
JAMA 1998;280:1008-1010.
FULL TEXT